Home  >  Information & Support  >  WSHLSC  >  Skills  >  Accessing HE/FE  >  University of Brighton Offer  >  Research & Knowledge Exchange

Research & Knowledge Exchange



The University of Brighton can provide access to world-leading experts in a variety of sectors. Our research and development projects range from one-off consultancy to long-term collaborations. They draw on our innovative research which is rooted in real world issues.

The most recent Research Excellent Framework (REF), the national instrument for assessing and measuring the quality and impact of research, ranked the University of Brighton 27th out of 128 for world-leading research impact, placing us in the top 25% in the sector.  And 92% of our research is rated as being world leading or internationally excellent in terms of the impact it makes to the economy and society


Within life, health and physical sciences our research centres address a wide range of scientific, medical, environmental, technological and mathematical challenges that face global society and economies.


For example, the Brighton Centre for Regenerative Medicine (BCRM) provides research and development (R&D) in a discipline aimed at the regeneration of diseased or traumatised tissues and organs using cutting-edge, minimally-invasive therapeutics.

Through breakthrough insights and innovation in biology, chemistry, nanotechnology, computer modelling, genomics, biomaterials and tissue engineering this research reflects the priorities of clinicians, industry and patients as well as experts in bioethics.  BCRM also has strong links with the Queen Victoria Hospital (East Grinstead) and the Blond McIndoe Research Foundation (with world famous heritage dating back to pioneering reconstructive surgery on badly injured pilots in World War 2).


Based on a similar model to BCRM, the University has recently (Jan 2016) launched the Brighton Centre for Medicines Optimisation.  This research centre will promote highly collaborative work between health care providers and academic researchers in the University of Brighton.  It will address all aspects of medicines optimisation from understanding the genetic basis of differing patient responses to pharmaceuticals to behavioural science interventions leading improved patient compliance.  The Centre would welcome industry participation in its research, for example from pharmaceutical companies seeking to discover the best dosing regimes for specific groups of patients.


These R&D programmes will translate knowledge-based innovation from laboratory to the clinic and community.


Strong links with companies have led to the development of technologies currently undergoing industrial feasibility studies in all the main research areas. Specialised cell culture substrates for the pre-clinical handling of stem cells are under development in collaboration with Tissue Click Ltd and AvantiCell Science Ltd. The exploitation potential of novel soybean-based biomaterials is currently pursued through Brighton Wound Care Ltd. The commercialisation of biomaterials for cancer therapy has been achieved through the collaboration with Biocompatibles Ltd. Finceramica SpA is seeking to develop the next generation of their osteochondral defect regenerative medicine constructs to pioneering surface functionalisation developed by the Centre. Biomaterials for blood homeostasis are currently penetrating the market in partnership with MAST Carbon Ltd.

Details of research groups within the Life, Health and Physical Sciences can be found here: Life, health and physical sciences research groups.  Groups and research areas include:


  • Biomaterials  
  • Chemistry
  • Environment and Public Health
  • Stress, aging and disease (STRAND, which incorporates smaller groups working on diabetes, aging, cancer and genetic diseases)
  • Sensory neuroscience
  • Drug delivery
  • Zoonotic diseases
  • Software engineering
  • Computational intelligence
  • Product design


Cluster company example:

Allergy Therapeutics


Allergy Therapeutics, a European-based speciality pharmaceutical company, undertook R&D work using the Image Analysis Unit, including a Knowledge Transfer Partnership and numerous research fellowships.

The results from this collaboration helped the company to solve a range of R&D and production-based problems.

As a result of this successful partnership, the university and Allergy Therapeutics won the 2006 Sussex Business Enterprise Awards for the best interaction between business and a Sussex-based university.

To collaborate on research please contact our Business Helpdesk: Chantal Batchelor, +44 (0)1273 643 098, email businesshelpdesk@brighton.ac.uk


Access sources of funding


Various funding schemes are available through UK Research Councils, Innovate UK and many other funding organisations. For further details contact our Business Helpdesk:  Chantal Batchelor, (0)1273 643 098; email businesshelpdesk@brighton.ac.uk


Knowledge Transfer Partnerships


Over 250 companies have worked with the University of Brighton to innovate through a Knowledge Transfer Partnership, a national scheme which provides grant funding of up to 67%. We have worked on hundreds of strategic projects with organisations of all sizes and have one of the largest Knowledge Transfer Partnership (KTP) portfolios in the UK.

Companies who have worked with us have reported increases in turnover and productivity, as well as the development of award-winning products, processes, and services.

Knowledge Transfer Partnerships enable companies to access the resources and academic expertise they need to innovate and grow, with the funding model allowing a recent graduate to be recruited to lead each partnership project.

The latest statistics from funders Innovate UK show that, on average, the KTP business benefits are:

  • £113k one-off increase in net profit during the programme
  • Projected increase of over £1 million in annual profits before tax
  • The creation of two new jobs
  • Increase in skills of existing staff


A project with Allergy Therapeutics, referred to above, developed allergy vaccines with improved efficacy to treat immune hypersensitivity diseases. A further project with Sauflon Pharmaceuticals Ltd developed an antimicrobial contact lens and embedded novel screening methods to facilitate further research and development and quality control.

To find out more about KTP contact Dr Shona Campbell: Email: ktp@brighton.ac.uk; Tel: 01273 642 426


This website may use cookies to provide an improved experience. You can refuse these cookies by changing your browser settings.
To remove this message, click here to accept cookies.